Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone510-748-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$444.94 million
Profitability
Miscellaneous
Employees2,200
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra Inc (NYSE:PEN) announced its earnings results on Tuesday, August, 6th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.06. The business earned $134.20 million during the quarter, compared to the consensus estimate of $130.67 million. Penumbra had a net margin of 3.03% and a return on equity of 6.80%. Penumbra's quarterly revenue was up 22.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.15 earnings per share. View Penumbra's Earnings History.
When is Penumbra's next earnings date?
What guidance has Penumbra issued on next quarter's earnings?
Penumbra updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $535-540 million, compared to the consensus revenue estimate of $536.57 million.
What price target have analysts set for PEN?
8 brokerages have issued 1 year price objectives for Penumbra's shares. Their forecasts range from $152.00 to $185.00. On average, they expect Penumbra's share price to reach $170.17 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Penumbra.
What is the consensus analysts' recommendation for Penumbra?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.
Has Penumbra been receiving favorable news coverage?
Media stories about PEN stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Penumbra earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Penumbra.
Are investors shorting Penumbra?
Penumbra saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,370,000 shares, an increase of 11.6% from the August 30th total of 5,710,000 shares. Based on an average daily volume of 560,200 shares, the short-interest ratio is presently 11.4 days. Currently, 19.9% of the company's shares are short sold. View Penumbra's Current Options Chain.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD) and Nevro (NVRO).
What other stocks do shareholders of Penumbra own?
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
- Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
- Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
- Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)
Who are Penumbra's major shareholders?
Penumbra's stock is owned by many different of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.03%), State of Alaska Department of Revenue (0.02%), Crossmark Global Holdings Inc. (0.01%), Campbell & CO Investment Adviser LLC (0.01%), Envestnet Asset Management Inc. (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which institutional investors are buying Penumbra stock?
PEN stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Crossmark Global Holdings Inc., State of Alaska Department of Revenue, Envestnet Asset Management Inc., Campbell & CO Investment Adviser LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $147.21.
How big of a company is Penumbra?
Penumbra has a market capitalization of $5.12 billion and generates $444.94 million in revenue each year. The company earns $6.60 million in net income (profit) each year or $0.51 on an earnings per share basis. Penumbra employs 2,200 workers across the globe.View Additional Information About Penumbra.
What is Penumbra's official website?
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (NYSE PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
